Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 19 crawled time : 00:20 save search
Combining Microbubbles & Cell Sorting for Quick & Efficient Cell Isolation
Published: 2022-03-19 (Crawled : 00:20) - thermogenesis.com
THMO | $0.65 49
|
Health Technology
| Email alert
Add to watchlist
cel
Thermogenesis Holdings CEO, Dr. Chris Xu, featured in BioPharm International Q&A Article
Published: 2022-03-19 (Crawled : 00:20) - thermogenesis.com
THMO | $0.65 49
|
Health Technology
| Email alert
Add to watchlist
ceo international tiona
Egg freezing, IVF and surrogacy: Fertility benefits have evolved to become the ultimate workplace perk
Published: 2022-03-19 (Crawled : 00:20) - progyny.com
PGNY | $33.2 0.42% 22K
|
Commercial Services
| Email alert
Add to watchlist
work
The Great Resignation is here: How to cultivate loyalty with family-focused benefits
Published: 2022-03-19 (Crawled : 00:20) - progyny.com
PGNY | $33.2 0.42% 22K
|
Commercial Services
| Email alert
Add to watchlist
MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
label one therapy cancer mirvetuximab phase 3
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent, Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
phase 2 one cancer mirvetuximab
Mirvetuximab Soravtansine, a Folate Receptor Alpha Targeting Antibody-Drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
drug ovarian cancer cancer mirvetuximab antibody
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
ovarian cancer results cancer mirvetuximab
DEADLINE: Grab Holdings Limited f/k/a Altimeter Growth Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GRAB; GRABW
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
GRAB | $3.415 1.94% 6M
|
n/a
| Email alert
Add to watchlist
growth deadline
DEADLINE: Celsius Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CELH
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
CELH | News | $70.64 1.22% 130K
|
Consumer Non-Durables
| Email alert
Add to watchlist
cel deadline
DEADLINE APPROACHING: Investors in Telefonaktiebolaget LM Ericsson with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ERIC
Published: 2022-03-19 (Crawled : 00:20) - prnewswire.com
ERIC | News | $5.25 -0.19% 780K
|
Electronic Technology
| Email alert
Add to watchlist
deadline
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
Published: 2022-03-19 (Crawled : 00:20) - globenewswire.com
CLABF | $0.1576 -0.13% 0
|
Process Industries
| Email alert
Add to watchlist
one potential
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.625 165.81% 5.5M
|
AGBA | $2.615 109.2% 14M
|
Finance
EDBL | News | $7.37 96.01% 650K
|
PALI | $7.64 54.97% 14M
|
Manufacturing
OPRT | News | $3.19 41.78% 3M
|
Finance
PEGY | $0.0629 37.34% 110M
|
Manufacturing
MLEC | $1.87 33.57% 1.6M
|
n/a
ATGL | $3.66 27.97% 150K
|
KULR | $0.5446 22.0% 6.8M
|
Manufacturing
MDIA 4 | $2.205 21.15% 150K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.